- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
- Device · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 24
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 38 more
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 136
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 104 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 49 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab 30 mg, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
- Conditions
- Atopic Dermatitis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more
- Conditions
- Chronic Pruritus of Unknown Origin
- Interventions
- nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fountain Valley, California + 22 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years to 54 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Healthy Volunteers
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Lincoln, Nebraska
- Conditions
- Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis, Primary Sclerosing Cholangitis
- Interventions
- Nemolizumab-ilto
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Prurigo Nodularis
- Interventions
- Not listed
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 57
- States / cities
- North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
- Conditions
- Lichen Plano-Pilaris
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- The Skin Center Dermatology Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New City, New York
- Conditions
- Systemic Sclerosis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Arlington, Texas
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Nemolizumab
- Biological
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Lichen Sclerosus of Vulva
- Interventions
- Nemolizumab 30 mg
- Biological
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 14
- States / cities
- Fountain Valley, California • San Diego, California • Vista, California + 11 more
- Conditions
- Atopic Dermatitis
- Interventions
- Nemolizumab, CYP 450 Substrates
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Saint Joseph, Missouri
- Conditions
- Chronic Kidney Disease Associated Moderate to Severe Pruritus
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 47
- States / cities
- Bakersfield, California • Glendale, California • La Palma, California + 40 more
- Conditions
- Atopic Dermatitis
- Interventions
- nemolizumab (CIM331), Placebo
- Drug · Other
- Lead sponsor
- Chugai Pharmaceutical
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • San Diego, California • Miami, Florida + 13 more